News

Each unit will consist of one common share and one-half of one share purchase warrant. Each whole share purchase warrant shall entitle the holder to acquire one common

The additional contribution will be applied to the development of the company’s novel antibiofilm topical wound gel containing its patented DispersinB technology. DispersinB wound gel is being developed

ROX-888 is an intranasal formulation of ketorolac, a non-steroidal anti-inflammatory drug, designed to provide ambulatory patients with a convenient, potent, and fast-acting option for acute pain relief, without

Once-daily fluticasone furoate (FF) produced statistically significant improvements in patients’ lung function (trough FEV1) compared to placebo (p < 0.05) in each of the three study populations and

The company also reported the following financial and operational achievements: $0.03 diluted earnings per share and a 5.1% increase in revenue for the three months ended December 31,

Mr Winzer has served as executive vice president and CFO of Avalon Pharmaceuticals since July 2007. Dr Keith assumed the position of president and COO of Panacea Pharmaceuticals

According to the company, the primary endpoint of change in percent predicted forced vital capacity (FVC) at week 72 was met with statistical significance in Capacity 2 (p=0.001),

Under the terms of the agreement, Health Discovery Corporation (HDC) will receive payments, royalties and additional undisclosed financial considerations. Stephen Barnhill, chairman and CEO of HDC, said: “We

Under the terms of the agreement, Debiopharm will make an up-front payment to Pharmaleads, as well as further payments as Pharmaleads reaches predefined development milestones. Following authorization from